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ORIGINAL RESEARCH
GPVI (Glycoprotein VI) Interaction With 
Fibrinogen Is Mediated by Avidity and the 
Fibrinogen αC-Region
Rui-Gang Xu ,* Julia S. Gauer ,* Stephen R. Baker, Alexandre Slater , Eleyna M. Martin , Helen R. McPherson ,  
Cédric Duval , Iain W. Manfield , Arkadiusz M. Bonna , Steve Watson, Robert A.S. Ariëns
OBJECTIVE: GPVI (glycoprotein VI) is a key molecular player in collagen-induced platelet signaling and aggregation. Recent 
evidence indicates that it also plays important role in platelet aggregation and thrombus growth through interaction with 
fibrin(ogen). However, there are discrepancies in the literature regarding whether the monomeric or dimeric form of GPVI 
binds to fibrinogen at high affinity. The mechanisms of interaction are also not clear, including which region of fibrinogen is 
responsible for GPVI binding. We aimed to gain further understanding of the mechanisms of interaction at molecular level 
and to identify the regions on fibrinogen important for GPVI binding.
APPROACH AND RESULTS: Using multiple surface- and solution-based protein-protein interaction methods, we observe that 
dimeric GPVI binds to fibrinogen with much higher affinity and has a slower dissociation rate constant than the monomer due 
to avidity effects. Moreover, our data show that the highest affinity interaction of GPVI is with the αC-region of fibrinogen. We 
further show that GPVI interacts with immobilized fibrinogen and fibrin variants at a similar level, including a nonpolymerizing 
fibrin variant, suggesting that GPVI binding is independent of fibrin polymerization.
CONCLUSIONS: Based on the above findings, we conclude that the higher affinity of dimeric GPVI over the monomer for 
fibrinogen interaction is achieved by avidity. The αC-region of fibrinogen appears essential for GPVI binding. We propose that 
fibrin polymerization into fibers during coagulation will cluster GPVI through its αC-region, leading to downstream signaling, 
further activation of platelets, and potentially stimulating clot growth.
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GPVI (glycoprotein VI), expressed by platelets and megakaryocytes, is widely accepted as an activation receptor for collagen, playing a critical role in platelet 
activation and thrombus initiation,1,2 as well as in preven-
tion of inflammation-induced hemorrhage.3 The impor-
tance of GPVI in thrombus formation is emphasized by 
observations that absence of GPVI impairs experimen-
tal thrombosis in mouse models, including no occlusive 
thrombus formation observed in knockout mice following 
FeCl3 injury.
4–6 Conversely, absence of GPVI in mice 
has minor effects on haemostasis, and GPVI-deficient 
patients present with a mild bleeding diathesis.7–9 These 
observations suggest that GPVI is a promising antithrom-
botic target with a minor impact on hemostasis.10 Upon 
vessel injury, GPVI interacts with exposed subendothelial 
collagen, resulting in platelet signaling, activation, and 
thrombus formation.11 The extracellular region of GPVI 
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related to FcαR and natural killer receptors of the immu-
noglobulin superfamily.12,13
Fibrinogen is essential for platelet aggregation and 
blood coagulation. It contains 2 distal D-regions and a 
central E-region, connected by 2 α-helical coiled-coils. 
Each fibrinogen molecule has 2 αC-regions, composed 
by the C-terminal two-thirds of the Aα-chains14 (Fig-
ure I in the Data Supplement). It has been suggested 
that the αC-region folds back from the distal end and 
interacts with the E-region via its relatively compact 
C-terminal domain.15,16 Initiation of fibrin polymerization 
is triggered by thrombin, through knob-hole interactions 
between the D- and E-regions of adjacent molecules. 
Polymerized fibrin is strengthened by FXIIIa-mediated 
intermolecular cross-linking of the αC- and D-regions. 
Early-stage fibrinogen degradation products by plasmin 
or trypsin include X-fragment (truncated αC-region)16 
and fragment Y (truncated αC-region and one of the 
2 D-regions). Later-stage degradation products D- and 
E-fragments are released during prolonged proteolysis 
time. D-dimer is a final degradation product of polymer-
ized fibrin that has been cross-linked by FXIIIa (Figure I 
in the Data Supplement).17,18
Recently, a role for GPVI in thrombus growth inde-
pendent of its interaction with collagen has been 
reported, with several studies indicating that GPVI binds 
fibrin(ogen).19–24 Although one study showed binding of 
monomeric GPVI extracellular domain to immobilized 
fibrinogen19 and another detected low levels of dimeric 
GPVI (extracellular domain fused by IgG-Fc, also called 
GPVI-Fc or GPVI-Fc2) binding to fibrinogen,
22 all of the 
other reports focused on GPVI binding to fibrin.20,21,23 The 
breakdown product of fibrin, D-dimer, has been shown 
to bind GPVI in 2 reports22,23 and to act as a competi-
tive inhibitor in displacement studies.19,23 Collagen and 
CRP-XL (cross-linked collagen-related peptide) also dis-
place D-dimer/D-fragment binding suggesting that the 
binding site of collagen and fibrin(ogen) on GPVI may 
overlap.22 All previous interaction studies used immobi-
lized fibrin(ogen) or its fragments. Whether fibrinogen 
and fibrin also interact with GPVI in solution is unclear 
as immobilized fibrin(ogen) may adopt a different con-
figuration. Another unresolved question is whether other 
regions of fibrinogen interact with GPVI. Finally, there 
are discrepancies in the literature as to whether mono-
meric or dimeric GPVI (Figure II in the Data Supplement) 
shows higher affinity for fibrin(ogen).25
Here, we investigate the molecular interaction mecha-
nisms of GPVI and fibrin(ogen), using a combination of 
4 different protein-protein interaction methods, that is, 
ELISA, microscale thermophoresis (MST), surface plas-
mon resonance (SPR), and atomic force microscopy 
(AFM), to gain detailed understanding of the binding 
affinity and kinetics while also identifying the GPVI bind-
ing regions on the fibrinogen molecule. We also investi-
gate the effects of fibrin polymerization on GPVI binding 
using a novel recombinant fibrinogen mutant that is 
unable to polymerize on conversion to fibrin by thrombin, 
called nonpolymerizing (previously also called double-
Detroit in Duval et al26) fibrinogen. Our data show that 
both monomeric and dimeric GPVI bind the αC-region 
of fibrinogen and that their affinities and kinetic profiles 
are distinct from each other based on avidity. Binding is 
independent of fibrin polymerization as similar binding 
profiles were observed for recombinant wild-type, non-
polymerizing, and plasma-purified fibrin.
MATERIALS AND METHODS
The data that support the findings of this study are available 
from the corresponding author upon reasonable request.
Enzyme-Linked Immunosorbent Assays
ELISAs were performed based on previously described meth-
ods,23 with slight modifications. In brief, 96-well Maxisorp Nunc-
immuno plates were coated with 10 nmol/L BSA, purified 
fibrinogen, type 1 collagen fibrils or CRP-XL, or 100 nmol/L 
GPVI-Fc/GPVI monomer, in duplicates overnight at 4 °C. 
Immobilized fibrinogen was converted to fibrin by addition of 
0.1 U/mL thrombin for 20 minutes at room temperature. Plates 
were washed to remove excess protein and blocked with 3% 
BSA-PBS for 1 hour at room temperature. After washing, plates 
were incubated with purified GPVI constructs at 100 nmol/L, 
or BSA control, for 1 hour. For concentration-dependent experi-
ments, 0 to 400 nmol/L GPVI constructs were used, and 100 
Nonstandard Abbreviations and Acronyms
AFM atomic force microscopy




SPR surface plasmon resonance
Highlights
• Fibrinogen interacts with monomeric and dimeric 
GPVI (glycoprotein VI) with distinct affinities and 
kinetic profiles. The higher affinity of dimeric GPVI 
for fibrinogen is due to increased avidity.
• The αC-region of fibrinogen is crucial for high-affin-
ity GPVI binding and playing a more important role 
than other fibrinogen regions in the interaction.
• Fibrin polymerization is not required for GPVI bind-
ing, as similar binding profiles of GPVI monomer and 
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nmol/L CRP-XL was preincubated with matching concentra-
tions of GPVI constructs for 15 minutes in competition assays. 
In addition, for GPVI displacement experiments 0 to 100 
nmol/L of either GPVI construct was preincubated with 100 
nmol/L of the alternative construct for 15 minutes before addi-
tion to the plate. After incubation with GPVI constructs, plates 
were washed and incubated for 1 hour at room temperature 
with either 1:10 000 goat anti-human IgG-Fc HRP-conjugated 
antibody to detect binding of dimeric GPVI-Fc or 1:10 000 
rabbit anti–6-His HRP-conjugated antibody to detect mono-
meric His-tagged GPVI. After washing, the binding of GPVI 
to immobilized substrate was visualized using 3,3’,5,5’-tetra-
methylbenzidine. The reaction was stopped by addition of 1 M 
H2SO4 and the optical density was read at 450 nm. All binding 
values obtained were normalized to their corresponding BSA 
controls to account for background binding levels. Results were 
expressed as an average of 3 repeats ±SEM.
Microscale Thermophoresis
Each of the 16 binding reactions was prepared by mixing 10 
μL of 50 nmol/L fluorescein isothiocyanate (FITC)-labeled 
GPVI monomer or dimer in buffer containing 20 mmol/L 
HEPES pH 7.5, 50 mmol/L NaCl with 10 μL of the respec-
tive fibrin(ogen) or their proteolytic fragments serially diluted 
using the same buffer. The reactions were incubated at 4 °C 
for 5 minutes, followed by centrifugation at 17 000g to remove 
protein aggregates that may interfere with the measurement. 
The supernatants were loaded into standard treated capil-
laries before data collection using a Monolith NT.115 Series 
microscale thermophoresis instrument. The excitation/emission 
wavelength was set at 493/521 nm (blue channel). The LED 
power was set at 75%, whereas 10% MST power was used for 
each binding experiment. Data were collected at 23 °C in 2 to 3 
replicates. KD was obtained by fitting the binding curve with the 
quadratic solution for the fraction of fluorescent molecules that 
formed the complex, calculated from the law of mass action 
(1:1 binding model).27 KD was presented as mean±SD. When 
the binding curve was not saturated, the KD was estimated as 
greater than the GPVI concentration that generates half of the 
maximum binding signal.
GPVI-Fibrinogen/αC Fragments Binding and 
GPVI Intermolecular Interaction by Surface 
Plasmon Resonance
All SPR binding experiments were conducted using a Biacore 
3000 instrument (GE Healthcare, Piscataway, NJ) using a 
binding buffer containing 10 mmol/L HEPES, pH 7.4, and 
140 mmol/L NaCl, 0.05% tween 20. Biotinylated fibrinogen, 
monomeric, and dimeric GPVI were prepared by adding EZ-link 
NHS-LC-biotin dissolved in anhydrous dimethyl sulfoxide 
(DMSO) to the proteins dialyzed in PBS at a molar ratio of 2:1. 
The reactions were left on ice for 1 hour, followed by purifica-
tion using NAP-5 desalting column, equilibrated with PBS, to 
remove excess unreacted biotin. Before ligand immobilization, 
streptavidin chips were conditioned with 3 consecutive 1-min-
ute injections of 1 M NaCl in 50 mmol/L NaOH at 30 μL/
min. Biotinylated proteins were then diluted to 10 nmol/L and 
immobilized on streptavidin sensor chips at 5 μL/min in PBS 
buffer. Biotinylated fibrinogen, monomeric, and dimeric GPVI 
were immobilized on flow cell 2 (1500 RU), 3 (140 RU), and 
4 (600 RU) respectively, whereas flow cell 1 was left without 
immobilized protein. The density of immobilized molecules on 
flow cell 3 and 4 are equivalent, given their different molecu-
lar weights. Monomeric and dimeric GPVI were flowed over 
at concentrations up to 20 μM at a flow rate of 40 μL/min 
at 25 °C, by injecting 8 to 10 samples of the 2 proteins made 
from 2-fold serial dilutions plus 2 buffer injections. For GPVI-
αC fragments interaction, the experiment was performed as 
mentioned above, except that biotinylated αC fragments Aα 
221 to 391, 368 to 610, and 221 to 610 were immobilized 
on flow cell 2 (80 RU), 3 (120 RU), and 4 (180 RU), respec-
tively, and that only dimeric GPVI was used as analyte. The 
density of immobilized molecules on flow cell 2, 3, and 4 are 
equivalent, given their different molecular weights. Response 
signals obtained from flow cell 1 and buffer injections were 
subtracted in the data processing to obtain the final response 
curves. The data obtained from 5 lowest analyte concentra-
tions where binding was observed were selected and fitted 
with 1:1 Langmuir model where association rate constant 
(ka), dissociation rate constant (kd), and dissociation constant 
(KD) were obtained.
28 ka, kd, and KD values were presented as 
mean±SD; N=3 for GPVI-fibrinogen interaction and N=2 for 
GPVI-αC fragments interaction. For GPVI-fibrinogen interac-
tion, the highest analyte concentration curves were omitted in 
the fitting because they are less likely to follow the 1:1 interac-
tion model than the lowest ones.
AFM Imaging of GPVI/Fibrinogen Interactions
AFM images were taken using a surface of freshly cleaved 
mica that was treated with 50 µL of 2 mmol/L NiCl2 for 5 min-
utes. Following treatment, the surface was rinsed with deion-
ized water and dried with nitrogen gas. For imaging of GPVI/
fibrinogen interactions, GPVI monomer or dimer was incubated 
with fibrinogen at a 1:1 molar ratio for at least 2 hours in HBS. 
The solution was diluted to a final concentration of 2.5 µg/
mL (8 nmol/L, fibrinogen) in HBS, added to the pretreated 
mica surface for 10 s, diluted with 50× deionized water for 
10 s, and dried under nitrogen gas. High-resolution imaging 
was done using a Nanoscope IIIa Multimode AFM (Bruker, 
Santa Barbara, CA) in tapping mode with a scan rate of 0.8 
Hz. All measurements were done in air using silicon cantilevers 
(TESPA-V2, Bruker Santa Barbara, CA) with a typical radius 
of 7 nm. Three to 5 images were taken from each sample and 
samples were repeated at least 3×. Standard flattening of 
images was performed.
For expression and purification of recombinant GPVI and 
fibrinogen/αC fragments, purification of plasma fibrinogen/αC 
fragments, preparation and purification of X-, D-, E-fragment 
and D-dimer, FITC labeling of GPVI, SD test, and additional 
SPR experiments, see supplemental methods.
Statistical Analysis
For ELISA assays, all data were checked for normality by a 
Shapiro-Wilk test (alpha=0.05). Comparisons between related 
groups were performed by paired t test. Differences between 
samples and control (BSA or 0 nmol/L of GPVI-Fc/GPVI mono-
mer) were compared using one-way ANOVA or Kruskal-Wallis 
test for multiple group comparisons, followed by Tukey-Kramer 
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Data analysis was performed using OriginPro 2017/2018 and 
Prism 8 GraphPad 2020. P<0.05 were considered to indicate 
statistical significance.
RESULTS
Surface-Based Fibrinogen and GPVI Interaction
The binding of monomeric and dimeric GPVI to immo-
bilized fibrinogen was analyzed by ELISA. Both forms 
showed concentration-dependent binding to fibrinogen 
(Figure 1A), although the GPVI monomer appeared to 
bind at lower concentrations than the dimer in this assay. 
It was further observed that binding between monomeric 
GPVI and fibrinogen could be displaced by preincuba-
tion with CRP-XL (Figure 1B), indicating that CRP-XL 
and fibrinogen likely share an overlapping binding site on 
GPVI. We next compared the ability of fibrinogen variants 
to bind GPVI, including plasma-purified, recombinant 
wild-type, nonpolymerizing-fibrinogen, and fibrin.26 Simi-
lar binding profiles to GPVI monomer and dimer were 
observed for all fibrinogen variants, suggesting that fibrin 
polymerization is not required for GPVI binding (Figure 1C 
dimer and 1D monomer). Indeed, when these fibrinogen 
variants were converted to fibrin through thrombin treat-
ment, their binding profiles to GPVI remained similar (Fig-
ure 1C dimer and 1D monomer). We also observed that 
the dimeric form of GPVI appeared to partially displace 
the binding of GPVI monomer to immobilized fibrinogen, 
whereas addition of GPVI monomer had no impact on 
dimeric GPVI binding (Figure III in the Data Supplement). 
Binding of different types of fibrinogen to immobilized 
GPVI dimer and monomer was also observed (Figure III 
in the Data Supplement), confirming interaction of GPVI 
with fibrinogen in both orientations.
Figure 1. Interaction of GPVI (glycoprotein VI)-Fc and GPVI monomer with immobilized fibrinogen measured by ELISA.
A, Concentration-dependent (0-400 nmol/L) binding of immobilized plasma-purified fibrinogen to GPVI-Fc (blue) and GPVI monomer 
(orange); (B) Immobilized CRP-XL (cross-linked collagen-related peptide) and IF-1 fibrinogen binding to 100 nmol/L GPVI monomer (black) 
and displacement of binding by 100 nmol/L CRP (gray); Binding of (C) GPVI-Fc dimer and (D) GPVI monomer to collagen, immobilized IF-1, 
recombinant wild-type (WT) and recombinant nonpolymerizing (NP) fibrinogen and fibrin (immobilized fibrinogen followed by cleavage by 
thrombin). Differences in optical density (OD) were compared between groups (B) or between immobilized ligand and BSA control (C and D); 
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GPVI Binds to Fibrinogen and CRP-XL in 
Solution
We next performed solution-based MST experiments 
by titrating fibrinogen to FITC-labeled GPVI mono-
mer and dimer, respectively (Figure 2A and 2B). A 
saturable profile was observed for fibrinogen binding 
to dimeric GPVI, with a KD1:1 of 99±2 nmol/L. Inter-
estingly, no saturation of binding was observed when 
titrating up to 10 μM fibrinogen into monomeric GPVI. 
The KD1:1 of the latter interaction was estimated at >4 
µmol/L (Table I in the Data Supplement). These data 
indicate that fibrinogen is able to bind both dimeric 
and monomeric GPVI in solution but with at least an 
order of magnitude higher affinity for dimeric than 
monomeric GPVI.
To analyze if GPVI binds to CRP-XL in solution by 
MST, we titrated CRP-XL into FITC-labeled monomeric 
and dimeric GPVI, respectively. As the CRP-XL con-
centration increased, the initial fluorescence intensity 
was reduced (Figure 2C and 2D), suggesting that 
CRP-XL interacts with both monomeric and dimeric 
GPVI, inducing quenching of the fluorescence. The 
fluorescence signal changes are specific to the bind-
ing of CRP-XL and were not caused by experimental 
artifacts, such as loss of fluorescent molecules due 
to surface absorption in which the fluorescence inten-
sities of all samples were measured again after pro-
tein denaturation (see SD test and Figure IV in the 
Data Supplement). The binding data were fitted to a 
1:1 stoichiometry model, resulting in a KD1:1=5±0.8 
μM and 603±207 nmol/L (hypothetical KD calculated 
using the molar concentration of CRP-XL, monomeric 
equivalent), for the interaction of CRP-XL with mono-
meric and dimeric GPVI, respectively (Table I in the 
Figure 2. GPVI (glycoprotein VI)-CRP-XL (cross-linked collagen-related peptide)/fibrinogen interaction analysis using 
microscale thermophoresis.
A, Fibrinogen binds to fluorescein isothiocyanate (FITC)-monomeric GPVI at KD of >4 μM, estimated as greater than the GPVI concentration 
that generates half of the maximum binding signal; (B) fibrinogen binds to FITC-dimeric GPVI at KD of 99±2 nmol/L; (C) CRP-XL binds to 
FITC-monomeric GPVI at KD of 5±0.8 μM; (D) CRP-XL binds to FITC-dimeric GPVI at KD of 603±207 nmol/L. Data were plotted using 3 
independent replicates from which KD values were obtained through fitting all the data with 1:1 interaction model using NanoTemper Analysis 
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Data Supplement). Our observations that CRP-XL 
binds to dimeric GPVI more tightly than monomeric 
GPVI is in good agreement with the affinity data 
reported in the literature.29–31
Surface Plasmon Resonance Analysis of 
Fibrinogen-GPVI Interaction
To gain further insight into the kinetic profiles of GPVI-
fibrinogen interactions, we performed SPR by immobiliz-
ing biotin-labeled fibrinogen as ligand on a streptavidin 
sensor chip with preimmobilized streptavidin. Monomeric 
and dimeric GPVI were flowed at various concentra-
tions as analytes over the low-density fibrinogen surface 
at up to 20 μM. Consistent with the MST data, distinct 
KD1:1 values of 2.4±0.3 μM for monomeric and 46±5 
nmol/L for dimeric GPVI (Figure 3A and 3B, Table II in 
the Data Supplement) were observed. Compared with 
monomeric GPVI, dimeric GPVI showed faster associa-
tion rate constant than the monomer (8.5±0.2×103 ver-
sus 5.7±0.2×102 M-1S-1) and much slower dissociation 
rate (6.1±0.1×10-4 versus 2.2±0.05×10-3 S-1; Table II in 
the Data Supplement). When GPVI dimer was flowed as 
analyte at 20 μM, the response units were higher than 
that expected for 1:1 interaction (observed at 803 RU 
versus theoretical 1:1 interaction at 507 RU, Figure V 
in the Data Supplement). This observation suggests that 
dimeric GPVI interacts with >1 site on fibrinogen. To con-
firm the findings in ELISA that GPVI-fibrin(ogen) binding 
is not affected by fibrinogen polymerization, we immo-
bilized nonpolymerizing-fibrinogen and converted it to 
fibrin using thrombin and determined their binding affini-
ties with GPVI dimer using SPR. As observed for plasma-
purified fibrinogen, nonpolymerizing-fibrinogen, and fibrin 
bound to GPVI dimer at a similar scale of KD1:1 (127±57 
nmol/L and 86±21 nmol/L, respectively, Figure VI in the 
Data Supplement), which supports the above findings 
using ELISA. The observed slight decrease of binding 
affinity for nonpolymerizing compared with plasma-puri-
fied fibrinogen is possibly due to an observed slight α-
chain degradation for nonpolymerizing-fibrinogen during 
expression in mammalian cells (Figure VII in the Data 
Supplement). Note that our data below have shown that 
this region of fibrinogen is crucial for GPVI binding (See 
Mapping Fibrinogen Regions for GPVI Binding Using 
Recombinant αC Fragments).
Figure 3. GPVI (glycoprotein VI)-fibrinogen and GPVI intermolecular interaction analysis using surface plasmon resonance with 
fitted KD values.
A, Monomeric GPVI binding to immobilized fibrinogen at KD of 2.4±0.3 μM; (B) dimeric GPVI binding to immobilized fibrinogen at KD of 46±5 
nmol/L. No apparent binding was observed for (C) monomeric GPVI binding to immobilized monomeric GPVI and (D) dimeric GPVI binding to 
immobilized dimeric GPVI. Data shown is one of 3 independent replicates from which KD values were obtained through fitting individual data 
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GPVI Intermolecular Interactions
It has been reported that the 2 GPVI extracellular domains 
in GPVI-Fc (dimeric GPVI) may have a specific dimeric 
conformation that accounts for its stronger binding pro-
file to collagen compared with monomeric GPVI.29 To gain 
further understanding on whether the 2 GPVI extracel-
lular domains could dimerize to support this conformation, 
we designed SPR experiments where the intermolecular 
interactions of GPVI were measured by flowing mono-
meric and dimeric GPVI over immobilized monomeric and 
dimeric GPVI, respectively (Figure 3C and 3D). Our data 
show that no apparent binding was observed for either 
GPVI monomer to monomer or dimer to dimer. Similarly, 
the 2 proteins showed a single-peak gel filtration profile, 
with estimated molecular weights corresponding to single 
copies of their theoretical monomeric molecular weight 
(Figure VIII in the Data Supplement), indicating that they 
cannot dimerize or form stable higher oligomers in solu-
tion under these experimental conditions, consistent with 
the weak intermolecular contact observed in the crystal 
structure30 (Figure IX in the Data Supplement). Although 
intermolecular interaction is not detected under our 
experimental conditions, it is possible that at physiological 
conditions GPVI receptors on the cell surface may still 
dimerize or cluster upon platelet activation.31–33
Mapping Fibrinogen Regions for GPVI Binding 
Using X-, D-, E-Fragment or D-Dimer
To pinpoint regions of fibrin(ogen) that are responsible 
for GPVI binding, we produced proteolytic fragments of 
fibrinogen and fibrin for binding analysis with monomeric 
and dimeric GPVI (Figures IB and X in the Data Supple-
ment). Binding affinities were first analyzed using MST. 
No binding was observed when 30 to 100 μM X-, D-, 
E-fragment or D-dimer were titrated into monomeric 
GPVI (Figure XI in the Data Supplement). Although all 
the fragments did bind to dimeric GPVI, the binding pro-
files were not saturable at the fragment concentrations 
used (Figure 4A through 4D). The binding affinities were 
estimated at micromolar level (>2 μM for X- fragment 
and >20 μM for D-, E-fragment and D-dimer). We next 
performed SPR experiments to verify the findings from 
MST and obtain kinetic information of the interaction. 
When X-fragment and D-dimer were immobilized as 
ligand, no clear bindings were observed for GPVI mono-
mer and dimer at 1 and 10 µmol/L, respectively (Fig-
ure XII in the Data Supplement). Binding was detected 
at a reversed orientation (immobilizing monomeric and 
dimeric GPVI as ligands and flow over fibrin[ogen] X-, 
D-, E-fragments or D-dimer as analytes). Although both 
monomeric and dimeric GPVI bound to fibrin(ogen) frag-
ments, binding was not saturable at 40 μM analytes 
concentration (Figure XIII in the Data Supplement, Fig-
ure 5A through 5D). The kinetics of binding between 
monomeric and dimeric GPVI to the fibrin(ogen) frag-
ments differed from each other, with monomeric GPVI 
having more rapid association and dissociation rate con-
stants than the dimer. This could explain why binding was 
not observed in MST for those proteins, as their rapid off 
rates suggest that a stable complex is not likely formed 
and, therefore, not detected in MST. The K
D was obtained 
for dimeric GPVI binding to X-fragment, D-dimer, D-frag-
ment, and E-fragment at 9±1, 28±3, 26±5, and 51±15 
μM, respectively (Table II in the Data Supplement). Due 
to the very rapid association and dissociation rates, the 
KD for monomeric GPVI binding to all the fragments 
could not be determined through fitting the kinetic data. 
The affinities were estimated from a simulated SPR sen-
sorgram similar to that observed by modifying the on and 
off rates for dimeric GPVI-X-fragment interaction. The 
simulation revealed that the KD for monomeric GPVI-
X-fragment interaction is at least >128-fold higher, at 
>1 mmol/L (Figure XIV in the Data Supplement), than 
that observed for dimeric GPVI-X-fragment interaction 
(9±1 μM). These data indicate that fibrinogen fragments 
interact with monomeric and dimeric GPVI with distinct 
affinities and kinetic profiles. Compared with the binding 
data obtained using full-length fibrinogen, which showed 
nano-molar affinity for GPVI, the data indirectly show a 
major role of the fibrinogen αC-region in GPVI binding, 
which is not present in any of the proteolytic fragments, 
but normally present in full-length fibrinogen.
Mapping Fibrinogen Regions for GPVI Binding 
Using Recombinant αC Fragments
To confirm the proposed major role of fibrinogen αC-
region in GPVI binding and identify specific binding 
regions on αC for GPVI recognition, we expressed 3 
recombinant fibrinogen αC fragments in Escherichia coli: 
full-length (Aα 221-610); N-terminal linker (Aα 221-391) 
and C-terminal globular domain (Aα 368-610)34–37 and 
purified them to homogeneity (Figure XV in the Data Sup-
plement). These fragments were immobilized, and binding 
affinities with GPVI dimer were quantified using SPR. No 
apparent binding was found when up to 20 μM of GPVI 
dimer was flowed over the N-terminal linker (Figure 5E). 
Binding was observed for the full-length and C-terminal 
globular domain to GPVI dimer, at 604±89 nmol/L and 
2.3±0.2 µmol/L, respectively (Figure 5F through 5G, 
Table II in the Data Supplement). These data directly show 
that αC-region is playing a more important role than other 
fibrinogen regions in GPVI-fibrinogen interaction.
Molecular Imaging of GPVI-Fibrinogen 
Interactions
To verify our observations from MST and SPR, and to 
gain further understanding of the structural regions of 
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AFM by mixing the 2 proteins and directly visualiz-
ing the interactions occurring and the resulting protein 
complexes (Figure 6). Monomeric GPVI appeared as an 
elongated globular structure (Figure 6A through 6D). 
The dimeric GPVI particles were observed adopting 2 
different forms, single nodular or binodular (Figure 6E 
through 6H). Given that the intermolecular interaction is 
very weak as observed in SPR (Figure 3C through 3D), it 
is likely that the single and binodular forms represent top 
and side views of the GPVI dimer molecule. In the side 
view, the GPVI part and Fc domain should be visualized 
as 2 nodules closely attached. In the top view, the GPVI 
part and Fc domain should overlap, visualized as a single 
nodule. Fibrinogen on the AFM images is readily recog-
nizable as a typical trinodular protein (D-E-D) with the 
highly flexible and disordered αC-regions visibly extend-
ing from the D-region. The αC-region can extend as far 
as the E-region and interact with this part of the mol-
ecule.38,39 Both GPVI proteins generated complexes with 
fibrinogen, by apparently interacting with the αC-region 
through many different topologies based on the disor-
dered nature of this region of the fibrinogen molecule 
(Figure 6A, 6C, 6E, 6G, and 6H). These data are con-
sistent with the SPR and MST data showing an order of 
magnitude drop in the affinity of GPVI when comparing 
binding to full-length fibrinogen with the X-fragment lack-
ing the αC-region, and the direct binding of recombinant 
full-length and C terminus of the fibrinogen αC-region to 
GPVI dimer shown by SPR, indicating that the αC-region 
is critical for the interaction of GPVI with fibrinogen.
DISCUSSION
Our study provides key molecular insights into the 
interaction of GPVI with fibrinogen, with 2 main central 
findings. First, we found that fibrinogen interacts with 
monomeric and dimeric GPVI via 2 distinct affinities and 
kinetics profiles. The higher affinity of dimeric GPVI for 
fibrinogen is likely due to increased avidity, based on 
the observations that binding to dimeric GPVI has much 
Figure 4. Mapping GPVI (glycoprotein VI)-fibrinogen binding sites using microscale thermophoresis.
Binding profiles of (A) X-fragment, (B) D-dimer, (C) D-fragment, and (D) E-fragment to fluorescein isothiocyanate (FITC)-dimeric GPVI at KD 
of >2 μM for X-fragment and >20 μM for D-, E-fragment and D-dimer. KD values were estimated as greater than the GPVI concentration that 
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Figure 5. Mapping GPVI (glycoprotein VI)-fibrinogen binding sites using surface plasmon resonance.
Binding profiles of (A) X-fragment, (B) D-dimer, (C) D-fragment, (D) E-fragment, (E) Aα 221-391, (F) Aα 368-610 and (G) Aα 221-610 to 
dimeric GPVI. No apparent binding was observed for Aα 221-391. Binding was observed for X-fragment, D-dimer, D-fragment, E-fragment, Aα 
368-610 and Aα 221-610 at KD of 9±1 μM, 28±3 μM, 26±5 μM, 51±15 μM, 2.3±0.2 µmol/L and 604±89 nmol/L, respectively. KD values 
were determined through fitting individual data with Langmuir 1:1 interaction model (black lines). Each KD value is the mean and SD of 3 
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slower dissociation kinetics than the monomer, and that 
no intermolecular interactions were found for GPVI. Sec-
ond, our data show the αC-region of fibrinogen as the 
key binding region for GPVI interaction, indicating that 
the αC-region is playing a more important role than any 
other fibrinogen regions for GPVI binding.
Previous studies reported similar affinities for the bind-
ing of GPVI to fibrinogen and fibrin, indicating that fibrin 
polymerization is not required for GPVI binding.20–22,25 
In agreement with this, we observed no differences in 
GPVI-fibrinogen and GPVI-fibrin binding profiles by 
ELISA. Furthermore, we obtained similar binding profiles 
Figure 6. Atomic force microscopy topography images of interactions between GPVI (glycoprotein VI) and fibrinogen.
The fibrinogen molecules are highlighted using 3 black circles for its D-E-D structure. The disordered fibrinogen αC-regions are visible as 
flexible appendices with reduced height (and therefore reduced brightness) from the D-region or close to the E-region. A–D, GPVI monomer 
are indicated with cyan circles; (E–H) GPVI dimer are indicated with magenta circles. The αC region of fibrinogen involved in GPVI binding is 
highlighted with triangles. Two structural isoforms of GPVI dimer were observed: one as a large single-domain globular protein and the other as 
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with our new fibrin mutant that is unable to polymerize26 
when compared with polymerized fibrin preparations, 
confirming that polymerization of fibrinogen into fibrin is 
not required to elicit GPVI binding. Although GPVI is able 
to bind both fibrinogen and fibrin, we hypothesize that 
platelet activation only occurs when GPVI is clustered, 
which should happen if fibrin is polymerized into fibers 
or film,40 but not with fibrinogen in solution. Platelet acti-
vation via GPVI-fibrinogen interaction should also occur 
when platelets are interacting with fibrinogen coated to 
a plate because the close proximity of fibrinogen coated 
to the surface will support clustering of GPVI on the 
platelet. This is supported by differences observed in 
GPVI-deficient platelet spreading on fibrinogen-coated 
surfaces compared with normal platelets.19
Our MST and SPR data suggest that although both 
monomeric and dimeric GPVI can interact with fibrino-
gen, dimeric GPVI showed higher affinity for fibrinogen 
than the monomer with a slower dissociation rate. Simi-
lar observations have also been made for other recep-
tor-ligand interactions, such as Eph-ephrins (Fc-fused) 
and KIR2D-HLA-G (disulfide-linked), as well as for 
engineered binding protein-ligand interactions, such as 
affibodies and bispecific antibodies.41–47 The increased 
affinity for the fused dimer to their binding partner accom-
panied by a slower dissociation rate over the monomer 
could be explained by the avidity effect. These findings 
are reminiscent of our observations for GPVI-fibrinogen 
interaction, as well as those reported for GPVI-collagen 
interaction.29 It is likely that the affinity increase with a 
slower dissociation rate for the GPVI dimer compared 
with the monomer when binding to fibrinogen can also 
be attributed to the similar avidity effect mediated by the 
increased valency in the interaction.48
Our SPR analysis of GPVI intermolecular interaction 
where no self-assembly was observed implies that the 
increased affinity for dimeric GPVI binding to fibrino-
gen is more likely dominated by avidity effects than a 
dimeric GPVI conformation. Similar avidity model may 
also be applicable to other multivalent GPVI ligands, 
such as collagen, where distinct apparent affinities were 
also observed when interacting with GPVI monomer and 
dimer.29 Nevertheless, the conditions in which the intra-
molecular interaction was analyzed in our study are dif-
ferent than those occurring physiologically, where the 
GPVI is presented with all parts of the receptor includ-
ing the stalk and cytoplasmic tail. Furthermore, the local-
ization of GPVI on the platelet surface may facilitate 
dimerization, which cannot be achieved under solution 
conditions. Therefore, it cannot be ruled out that GPVI 
receptors on the platelet surface could form a specific 
and functional dimer conformation when interacting with 
these ligands. The GPVI dimer conformation is supported 
by several reports using GPVI dimeric specific antibod-
ies and Fabs showing the presence of GPVI dimers on 
the platelet surface upon platelet activation.33,49–51 More 
in-depth studies utilizing structural approaches, such 
as Cryo-EM, crystallography, and NMR, are needed to 
elucidate the molecular and conformational detail of the 
complete GPVI receptor on platelet surface and how this 
underpins interactions with its various biological ligands.
Whether the monomeric or dimeric GPVI binds to 
fibrin(ogen) at high affinity has been a conflicting topic 
debated in the literature.19,22,23 Several possible reasons 
to account for the apparently conflicting results have 
been proposed, such as variations in GPVI constructs and 
binding assay conditions among different labs.25 Another 
important factor that could contribute to the confliction is 
the limitations of ELISAs.19,21,22 For example, nonspecific 
signals could be induced through cross-reactivity of the 
multiple protein components used in the assays.52 Dif-
ferences in affinity of antibodies to either monomeric or 
dimeric GPVI could also play a role in the discrepancies 
by producing different levels of signal, which is indirectly 
related to both the affinities of the antibodies as well as 
the affinities of GPVI for the ligands. More direct meth-
ods, such as SPR and MST, are needed to support these 
results. Another reason for the discrepancies in previous 
studies is the source and quality of the fibrinogen used. 
The αC-region that appears to contribute most of the 
binding affinity is susceptible to protein degradation and 
highly variable in different fibrinogen preparations. All the 
above are likely responsible for some of the discrepan-
cies reported in the literature.
Our data show that the fibrinogen αC-region, which 
has not yet previously been implicated in GPVI bind-
ing, plays an important role in interactions with GPVI, 
as shown by the observed direct interaction of recom-
binant αC fragments with GPVI and decreased binding 
affinity after removing the αC-region from fibrinogen in 
the X-fragment. Our data further suggest that the GPVI 
binding region lies in the C-terminal globular domain of 
the αC region, by comparing the binding profiles of the 
full-length, N and C terminus of the αC. Interestingly, 
the C terminus of the αC region binds to GPVI dimer 
at a lower affinity than the full-length αC fragment and 
fibrinogen, indicating that binding is likely stabilized by 
other parts of the fibrinogen molecule, consistent with 
the disordered nature of the αC-region. The fibrinogen 
αC-region contains several important binding sites for 
integrin receptors such as αIIbβ3,53 αvβ3,54 and αvβ1.55 
Moreover, it also interacts with several plasma proteins 
including FXIII,34 fibronectin,56 apolipoprotein,57 plasmin-
ogen,35 tPA (tissue-type plasminogen activator),35 and 
α2-antiplasmin,58 each of which plays important roles in 
haemostasis, thrombolysis and other vascular processes. 
The αC-region proves to play a key role in the interaction 
of fibrinogen with other proteins, leaving the D- and the 
E-regions available and solely accessible to drive fibrin 
polymerization through knob-hole binding. The αC-region 
extensions from the D-region thus act as long flexible 
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with important vascular functions into close contact with 
the generating fibrin network during blood clotting.
In conclusion, our data support that avidity is responsible 
for the higher affinity of dimeric GPVI binding to fibrinogen 
over the monomer, mediated through increased valency 
of interaction. Avidity-based mechanisms have been sug-
gested for similar protein interaction systems and, there-
fore, could be utilized by other multivalent GPVI ligands, 
such as collagen and anti-GPVI antibodies when interact-
ing with GPVI. These observations provide new insight into 
our understanding of the mechanism of GPVI interactions 
with its multivalent ligands and clarify some of the discrep-
ancies reported in the literature, explained by the limitation 
of ELISAs. Our analysis also suggests that the αC-region 
of fibrinogen is an essential and important region for 
fibrinogen-GPVI interaction, which shed light on how the 
interaction of fibrinogen and fibrin with GPVI receptor on 
the surface of platelet impact thrombosis. When coagula-
tion leads to the generation of fibrin and fibrin fibers, inter-
action with the fibers that are being generated clusters 
GPVI on the platelet surface (Graphical Abstract), leading 
to rapid signaling, platelet activation, and sustained blood 
clot growth away from the collagen surface that initially 
triggered clot formation at the site of injury. Future work 
should focus on pinpointing the exact binding motif for 
GPVI on the fibrin(ogen) αC-region. The outcome from 
such studies could contribute to the development of novel 
and safer antithrombotic inhibitor drugs targeting GPVI-
fibrin(ogen) interaction with the fibrin(ogen) αC-region.
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